

In the Claims:

This version of the claims replaces all prior claims.

1. (Currently amended) A method of treating a patient requiring long-term therapy following hematopoietic cell transplantation having graft-versus-host disease or following organ allograft transplantation having host-versus-graft disease, the method comprising long term topical oral administration of beclomethasone dipropionate a topically active corticosteroid wherein treatment is directed to tissue selected from the group consisting of intestine and liver and further wherein the beclomethasone dipropionate topically active corticosteroid is initially administered at least 29 days post transplantation through 56 days post transplantation.
2. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate topically active corticosteroid is administered orally at a dosage of 4 mg per day to 12 mg per day.
3. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue is intestinal mucosa.
4. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue is small bile ducts in the liver.

5. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue damage is inflammation.
6. (Previously presented) The method of claim 1 wherein the patient has tissue damage and the tissue damage is destruction of the mucosa of the intestine.
7. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate topically active corticosteroid is administered orally from day 29 to day 56 following hematopoietic cell transplantation.
8. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate topically active corticosteroid is administered in combination with prednisone and prednisolone at 2 mg/kg.
9. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate topically active corticosteroid is formulated for oral administration in the form of a pill, capsule or microsphere.
10. (Currently amended) The method of claim 7 wherein the beclomethasone dipropionate of topically active corticosteroid is formulated such that the pill, microsphere, or capsule dissolves in the stomach, small intestine or colon.
11. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate topically active corticosteroid

is formulated for oral administration in the form of an emulsion.

12. (Currently amended) The method of claim 1 wherein administration of the beclomethasone dipropionate ~~topically active corticosteroid~~ initiates following infusion of the hematopoietic cells.

13. (Currently amended) The method of claim 1 wherein administration of the beclomethasone dipropionate ~~topically active corticosteroids~~ ceases after 80 days following infusion of the hematopoietic cells.

14. (Previously presented) The method of claim 1 wherein the patient is the recipient of HLA-mismatched hematopoietic stem cells.

15. (Previously presented) The method of claim 1 wherein the patient is the recipient of unrelated donor hematopoietic stem cells, umbilical vein hematopoietic stem cells, or peripheral blood stem cells.

16. (Currently amended) The method of claim 1 wherein the beclomethasone dipropionate ~~topically active corticosteroid~~ is administered in combination with other prophylactic agents.

17.-18. (Canceled)